Heron Therapeuti (HRTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $59.08M
Last updated: Nov 17, 2026 at 11:06 AM ET
Heron Therapeuti (HRTX) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Heron Therapeuti reported EPS of -$0.03, in line with the -$0.03 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
HRTX's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
HRTX Earnings Call
The latest HRTX earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 40 quarters below that had an estimate, HRTX beat 18, missed 21 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $35.25M, down 7.7% from $38.21M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.03 | -$0.03 | -$0.03 - -$0.02 | 0.00% | In line | N/A | 2 | 0 up, 1 down | Nov 9, 2026 | $35.25M |
| Jun 30, 2026 | -$0.03 | -$0.02 | -$0.02 - -$0.02 | -50.00% | Miss | N/A | 1 | 0 up, 0 down | Aug 10, 2026 | $37.67M |
| Mar 31, 2026 | -$0.04 | -$0.02 | -$0.02 - -$0.02 | -100.00% | Miss | -500.0% | 1 | 0 up, 0 down | May 11, 2026 | $34.71M |
| Dec 31, 2025 | -$0.02 | -$0.03 | -$0.03 - -$0.03 | +33.33% | Beat | -200.0% | 1 | 0 up, 0 down | Feb 26, 2026 | $40.59M |
| Sep 30, 2025 | -$0.04 | -$0.01 | -$0.02 - $0.00 | -300.00% | Miss | N/A | 3 | 0 up, 0 down | Nov 4, 2025 | $38.21M |
| Jun 30, 2025 | -$0.02 | -$0.01 | -$0.02 - $0.00 | -100.00% | Miss | N/A | 3 | 0 up, 1 down | Aug 8, 2025 | $37.20M |
| Mar 31, 2025 | $0.01 | -$0.01 | -$0.01 - -$0.01 | +200.00% | Beat | N/A | 2 | 0 up, 0 down | May 6, 2025 | $38.90M |
| Dec 31, 2024 | $0.02 | -$0.03 | -$0.03 - -$0.02 | +180.00% | Beat | N/A | 2 | 1 up, 0 down | Feb 27, 2025 | $40.78M |
| Sep 30, 2024 | -$0.03 | -$0.04 | -$0.04 - -$0.03 | +25.00% | Beat | N/A | 3 | 0 up, 0 down | Nov 12, 2024 | $32.81M |
| Jun 30, 2024 | -$0.06 | -$0.05 | -$0.05 - -$0.02 | -20.00% | Miss | N/A | 4 | 0 up, 0 down | Aug 6, 2024 | $36.02M |
| Mar 31, 2024 | -$0.02 | -$0.09 | -$0.11 - -$0.07 | +77.78% | Beat | N/A | 3 | 0 up, 0 down | May 7, 2024 | $34.67M |
| Dec 31, 2023 | -$0.07 | -$0.15 | -$0.19 - -$0.13 | +53.33% | Beat | N/A | 3 | 0 up, 0 down | Mar 12, 2024 | $34.23M |
| Sep 30, 2023 | -$0.17 | -$0.30 | -$0.33 - -$0.23 | +43.33% | Beat | N/A | 4 | 0 up, 0 down | Nov 14, 2023 | $31.43M |
| Jun 30, 2023 | -$0.35 | -$0.23 | -$0.26 - -$0.19 | -52.17% | Miss | N/A | 5 | 0 up, 0 down | Aug 14, 2023 | $31.76M |
| Mar 31, 2023 | -$0.27 | -$0.20 | -$0.25 - -$0.13 | -35.00% | Miss | N/A | 4 | 0 up, 0 down | May 11, 2023 | $29.61M |
| Dec 31, 2022 | -$0.17 | -$0.28 | -$0.38 - -$0.12 | +39.29% | Beat | N/A | 4 | 0 up, 0 down | Mar 23, 2023 | $30.03M |
| Sep 30, 2022 | -$0.38 | -$0.39 | -$0.44 - -$0.30 | +2.56% | Beat | N/A | 5 | 0 up, 0 down | Nov 8, 2022 | $26.56M |
| Jun 30, 2022 | -$0.55 | -$0.54 | -$0.59 - -$0.37 | -1.85% | Miss | N/A | 5 | 0 up, 0 down | Aug 9, 2022 | $27.63M |
| Mar 31, 2022 | -$0.63 | -$0.52 | -$0.56 - -$0.30 | -21.15% | Miss | N/A | 5 | 0 up, 0 down | May 9, 2022 | $23.46M |
| Dec 31, 2021 | -$0.54 | -$0.58 | -$0.62 - -$0.51 | +6.90% | Beat | N/A | 5 | 0 up, 0 down | Feb 28, 2022 | $20.66M |
| Sep 30, 2021 | -$0.51 | -$0.60 | -$0.68 - -$0.56 | +15.00% | Beat | N/A | 5 | 0 up, 0 down | Nov 3, 2021 | $23.23M |
| Jun 30, 2021 | -$0.62 | -$0.57 | -$0.61 - -$0.49 | -8.77% | Miss | N/A | 5 | N/A | Aug 9, 2021 | $22.44M |
| Mar 31, 2021 | -$0.58 | -$0.53 | -$0.65 - -$0.48 | -9.43% | Miss | N/A | 6 | N/A | May 10, 2021 | $20.02M |
| Dec 31, 2020 | -$0.68 | -$0.65 | -$0.90 - -$0.50 | -4.62% | Miss | N/A | 7 | N/A | Feb 24, 2021 | $20.61M |
| Sep 30, 2020 | -$0.64 | -$0.62 | -$0.75 - -$0.51 | -3.23% | Miss | N/A | 7 | N/A | Nov 5, 2020 | $19.96M |
| Jun 30, 2020 | -$0.61 | -$0.60 | -$0.83 - -$0.55 | -1.67% | Miss | N/A | 8 | N/A | Aug 5, 2020 | $22.67M |
| Mar 31, 2020 | -$0.57 | -$0.67 | -$0.76 - -$0.56 | +14.93% | Beat | N/A | 8 | N/A | May 6, 2020 | $25.40M |
| Dec 31, 2019 | -$0.65 | -$0.56 | -$0.72 - -$0.45 | -16.07% | Miss | N/A | 9 | N/A | Mar 2, 2020 | $35.08M |
| Sep 30, 2019 | -$0.42 | -$0.58 | -$0.69 - -$0.48 | +27.59% | Beat | N/A | 9 | N/A | Nov 12, 2019 | $42.62M |
| Jun 30, 2019 | -$0.63 | -$0.62 | -$0.77 - -$0.49 | -1.61% | Miss | N/A | 10 | N/A | Aug 5, 2019 | $36.66M |
| Mar 31, 2019 | -$0.80 | -$0.50 | -$0.64 - -$0.28 | -60.00% | Miss | N/A | 9 | N/A | May 9, 2019 | $31.60M |
| Dec 31, 2018 | -$0.63 | -$0.46 | -$0.56 - -$0.37 | -36.96% | Miss | N/A | 9 | N/A | Feb 22, 2019 | $28.84M |
| Sep 30, 2018 | -$0.49 | -$0.44 | -$0.60 - -$0.29 | -11.36% | Miss | N/A | 9 | N/A | Nov 7, 2018 | $19.79M |
| Jun 30, 2018 | -$0.54 | -$0.68 | -$0.93 - -$0.53 | +20.59% | Beat | N/A | 10 | N/A | Aug 8, 2018 | $17.28M |
| Mar 31, 2018 | -$0.81 | -$0.88 | -$1.07 - -$0.44 | +7.95% | Beat | N/A | 12 | N/A | May 10, 2018 | $11.57M |
| Dec 31, 2017 | -$1.09 | -$0.79 | -$0.91 - -$0.69 | -37.97% | Miss | N/A | 11 | N/A | Feb 27, 2018 | $10.05M |
| Sep 30, 2017 | -$0.77 | -$0.86 | N/A | +10.47% | Beat | N/A | N/A | N/A | Nov 6, 2017 | $8.57M |
| Jun 30, 2017 | -$0.80 | -$0.91 | N/A | +12.09% | Beat | N/A | N/A | N/A | Aug 9, 2017 | $8.51M |
| Mar 31, 2017 | -$1.00 | -$0.91 | N/A | -9.89% | Miss | N/A | N/A | N/A | May 10, 2017 | $3.63M |
| Dec 31, 2016 | -$1.22 | -$1.23 | N/A | +0.81% | Beat | N/A | N/A | N/A | Feb 23, 2017 | $1.28M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.07, after -$0.09 the year before. It was -$4.55 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.07 | N/A |
| Dec 31, 2024 | -$0.09 | N/A |
| Dec 31, 2023 | -$0.86 | N/A |
| Dec 31, 2022 | -$1.73 | N/A |
| Dec 31, 2021 | -$2.25 | N/A |
| Dec 31, 2020 | -$2.50 | N/A |
| Dec 31, 2019 | -$2.50 | N/A |
| Dec 31, 2018 | -$2.47 | N/A |
| Dec 31, 2017 | -$3.66 | N/A |
| Dec 31, 2016 | -$4.55 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 2,700 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 2,701 | 7 | |
| 2026Q1 | Mar 31, 2026 | 5,021 | 9 | |
| 2025Q4 | Dec 31, 2025 | 3,908 | 9 | |
| 2025Q3 | Sep 30, 2025 | 4,106 | 11 | |
| 2025Q2 | Jun 30, 2025 | 3,714 | 9 | |
| 2025Q1 | Mar 31, 2025 | 3,240 | 7 | |
| 2024Q4 | Dec 31, 2024 | 3,865 | 9 | |
| 2024Q3 | Sep 30, 2024 | 3,629 | 9 |
2026Q2 Earnings Call
Opening remarks
Melissa Jarel Investor Relations Thank you, Operator, and good morning, everyone. Thank you for joining us on the Heron Therapeutics conference call today to discuss the company's financial results for the second quarter of 2026. With me today from Heron are Craig Collard, Chief Executive Officer; Ira Duarte, Executive Vice President, Chief Financial Officer; Bill Forbes, Executive Vice President, Chief Development Officer; Mark Hensley, Chief Operating Officer; and Kevin Warner, Senior Vice President, Medical Affairs Strategy and Engagement. For those of you participating in the conference call, slides are made available via webcast and can also be accessed via the Investor Relations page of our website following the conclusion of today's call. Before we begin, let me quickly remind you that during the course of this conference call, the company will make forward-looking statements. We caution you that any statement that is not a statement of historical fact is a forward-looking statement. This includes remarks about the company's projections, expectations, plans, beliefs, and future performance, all of which constitute forward-looking statements for the purposes of the Safe Harbor Provision under the Private Securities Litigation Reform Act of 1995. These statements are based on judgment and analysis as of the date of this conference call and are subject to numerous important risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties associated with the forward-looking statements made in this conference call and webcast are described in the Safe Harbor statement in today's press release and in Heron's public periodic filings with the SEC. Except as required by law, Heron assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes and does not intend to do so. And with that, I would now like to turn the call over to Craig Collard, Chief Executive Officer of Heron.
Craig Collard Chief Executive Officer Thanks, Melissa. Hello, everyone, and welcome to Heron Therapeutics' second quarter 2026 earnings call. Net revenue for the quarter was $37.7 million. That is growth from the first quarter, but it is below what we expected of ourselves. CINVANTI sales were up compared to Q1 in a highly competitive market, and ZYNRELEF grew 35% year-over-year, but both were slower than we anticipated. Turning to Slide 4, let me walk through the key updates from the quarter. The acute care franchise delivered revenue growth of 44% year-over-year. ZYNRELEF grew 35%, with average daily units growing 19% year-over-year. APONVIE grew 74% year-over-year and reached 23% share of the surgical NK-1 segment, up 2 points from the first quarter. And CINVANTI came in at $21.8 million, up from $20.5 million in the first quarter.
Frequently Asked Questions About HRTX
Did HRTX beat earnings estimates last quarter?
Heron Therapeuti reported EPS of -$0.03 for the quarter ended Sep 30, 2026, in line with the -$0.03 estimate.
What EPS do analysts expect from HRTX next quarter?
The consensus EPS estimate for Heron Therapeuti for the quarter ending Dec 31, 2026 is -$0.03 from 4 analysts, with estimates from -$0.04 to -$0.02.
How often does HRTX beat earnings estimates?
Heron Therapeuti beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -17.08%.
HRTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors